Canine and Feline Dermatology Drug Handbook

A double‐blinded, randomized, controlled, crossover evaluation of a zinc methionine supplement as an adjunctive treatment for canine atopic dermatitis

“…A zinc dose of 10–20 mg per day has been suggested for initial supplementation of zinc‐deficient human patients with AD . Dogs with zinc‐responsive dermatoses are often empirically dosed initially at 2 mg/kg per day of elemental zinc . The 1.6 mg/kg zinc provided by ZnS is just below this recommended dose.…”

Efficacy of fluralaner against canine generalized demodicosis

“…Over the years, treatment with topical amitraz (Ghubash, 2006;Kosh et al, 2012) and macrocyclic lactones such as avermectins and milbemycins (Sartor & Santarem, 2006;Singh et al, 2011) have been used as acaricidal therapy. However, the possibility of developing adverse effects, due to its administration, has been described (Sartor e Santarem, 2006;Delayte et al, 2006;Singh et al, 2011).…”

“…However, the possibility of developing adverse effects, due to its administration, has been described (Sartor e Santarem, 2006;Delayte et al, 2006;Singh et al, 2011). Additionally, macrocyclic lactones are not indicated for use in dogs with a mutation of ABCB1-1 (MDR-1) gene (Ghubash, 2006;Kosh et al, 2012).…”

Efficacy of oral sarolaner for the treatment of generalized demodicosis in dogs

“…Macrocyclic lactones, such as avermectins and milbemycins, can be used as acaricidal therapy. (Kosh et al, 2012) However, their adverse effects are principally related to neurotoxicity, including depression, stupor, coma, ataxia, mydriasis, tremors, emesis, drooling, and seizures (Singh et al, 2011). They are also contraindicated in breeds with a ABCB1-1 (MDR-1) mutation (Kosh et al, 2012).…”

“…(Kosh et al, 2012) However, their adverse effects are principally related to neurotoxicity, including depression, stupor, coma, ataxia, mydriasis, tremors, emesis, drooling, and seizures (Singh et al, 2011). They are also contraindicated in breeds with a ABCB1-1 (MDR-1) mutation (Kosh et al, 2012). Amitraz, a miticidal drug, is not indicated as first-line therapy (Kosh et al, 2012).…”